Lymphoma
The anti-CD20 monoclonal antibody rituximab is generally well tolerated
Published in Drug Week, September 5th, 2003
"The chimeric anti-CD20 monoclonal antibody rituximab has become part of the standard therapy for patients with non-Hodgkin's lymphoma (NHL)," researchers in Germany report.
"To date, more than 300,000 patients have been treated with rituximab worldwide, including patients with indolent and aggressive NHL, Hodgkin's disease, and other B-cell malignancies," wrote J. Boye and colleagues, University Hospital of Cologne, Department of Internal Medicine 1.
"Combination of rituximab with cytotoxic agents or cytokines has been explored in a number of different...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2003-09-05)
More Articles from Drug Week
- Antibiotic Resistance
Newly discovered inhibitors of bacterial lactamases may prevent resistance - Pain Medicine
Compound that acts on peripheral receptors may be promising treatment - Atherosclerosis
Patient enrollment completed in phase IIb CART-2 study with AGI-1067 - Breast Cancer
Trial tests treatment for postmenopausal cancer patients who relapse - Drug Development
PEDF could potentially treat a variety of angiogenesis-related disorders - Medulloblastoma
Cancer research center reports that retinoids kill childhood brain tumor cells - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
